BrainStorm Executive Leadership to Speak at DUPHAT 2026
BrainStorm's Executive Chairman Peter J. Pitts will deliver keynote addresses and moderate panel sessions at DUPHAT 2026. His topics include establishing an FDA Abraham Accords Office and restructuring NIH research grant models.
BrainStorm Executive Leadership is set to participate in DUPHAT 2026, a significant event for the pharmaceutical industry. Peter J. Pitts, Executive Chairman of BrainStorm and former Associate Commissioner for the U.S. Food and Drug Administration (FDA), has been invited to deliver two keynote presentations.
Pitts' talks will address the establishment of an FDA Abraham Accords Office, an initiative aimed at fostering collaboration and regulatory alignment. He will also present on restructuring the National Institutes of Health (NIH) research grant models, focusing on potential improvements to the funding process for medical research.
In addition to his keynote speeches, Pitts is scheduled to moderate expert panel sessions. These sessions will delve into topics such as translational pharmaceutical innovation and the impact of emerging technologies on the industry. The discussions are expected to provide insights into advancing drug development and healthcare solutions.
DUPHAT serves as a key forum for industry professionals to exchange knowledge and discuss future trends. BrainStorm's involvement, through Pitts' expertise, highlights the company's engagement with critical issues shaping pharmaceutical development and international regulatory landscapes.